Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Aditxt, Inc. (NASDAQ: ADTX), an innovative health platform, has announced a 1-for-8 reverse stock split effective March 9, 2026. This decision follows approval from stockholders at a special meeting on February 13, 2026, with the final ratio determined by the company’s board. Upon the split, every eight shares will be converted into one share, rounding any fractions up to the nearest whole share. As a result, the company will have around 517,856 common shares outstanding post-split, with a new CUSIP number of 007025877 assigned to the stock.

The primary purpose of the reverse stock split is to help Aditxt comply with Nasdaq’s minimum bid price requirements, an essential step for maintaining their listing on the exchange. Additionally, adjustments will be made to existing securities such as outstanding warrants and stock options, aligning their terms with the new share structure.

Aditxt is positioned as a social innovation platform, striving to accelerate health innovation through collaboration among research institutions, industry partners, and shareholders. The company aims to drive disruptive growth and address critical societal challenges through a democratized innovation model that values all stakeholder inputs.

In light of these developments, the company has urged investors to consider forward-looking statements regarding the anticipated effects of the reverse stock split and compliance with listing standards. These statements reflect the company’s strategic outlook, and caution that actual outcomes may differ due to various factors, as detailed in their latest filings with the Securities and Exchange Commission.

For more information, stakeholders can access Aditxt's definitive proxy statement filed on December 16, 2025, and reach out via investor relations.

Aditxt, Inc. (NASDAQ: ADTX) has announced a 1-for-8 reverse stock split set to take effect on March 9, 2026. This strategic move aims to help the company comply with Nasdaq's minimum bid price requirement, a common necessity for companies facing regulatory pressures. For investors, this announcement carries both short-term implications and longer-term considerations.

In the immediate term, the reverse split will consolidate shares, reducing the total number of shares outstanding from approximately 4.14 million to about 517,856. This consolidation may lead to a temporary increase in the stock price, as shares typically gain value when the number of shares is decreased. However, it’s important to recognize that reverse splits can often be symptomatic of underlying issues within the company, such as financial instability or operational challenges.

As Aditxt seeks to regain compliance with Nasdaq, investors should approach the stock with a cautious mindset. While a reverse split could provide a fresh start, it does not address fundamental questions regarding the company's financial health or growth prospects. Aditxt's business model, which focuses on accelerating health innovations, presents potential growth avenues. However, the ability to leverage this model effectively will be critical in determining long-term success.

Investors should closely monitor Aditxt's upcoming financial disclosures and market performance to gauge how effectively the company can execute its business plan post-split. As always, performing due diligence and considering risk factors, as outlined in Aditxt's filings, will be essential for any investment decision.

In summary, while the 1-for-8 reverse stock split is a significant step for Aditxt to remain listed on Nasdaq, potential investors should weigh this development against the company's overall health and market environment before making investment decisions.